(Q49137840)

18 February 2018

title

Cost-effectiveness evaluation of a quadrivalent human papillomavirus vaccine in Belgium. (English)

1 reference

18 February 2018

0 references

1 reference

Lieven Annemans

1

1 reference

18 February 2018

Vanessa Rémy

series ordinal

2

1 reference

18 February 2018

James Oyee

series ordinal

3

1 reference

18 February 2018

Nathalie Largeron

series ordinal

4

1 reference

18 February 2018

publication date

1 January 2009

1 reference

18 February 2018

published in

PharmacoEconomics

1 reference

18 February 2018

volume

27

1 reference

18 February 2018

issue

3

1 reference

18 February 2018

page(s)

231-245

1 reference

18 February 2018

The management of difficult anogenital warts

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200927030-00006

Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200927030-00006

Estimating the number needed to vaccinate to prevent diseases and death related to human papillomavirus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200927030-00006

Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200927030-00006

Economic burden associated with the management of cervical cancer, cervical dysplasia and genital warts in Belgium

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00019053-200927030-00006

The epidemiological and economic impact of a quadrivalent human papillomavirus vaccine (6/11/16/18) in the UK.

21 January 2018

1 reference

12 December 2020

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

1 reference

12 December 2020

Analysis of 13 million individual patient records pertaining to Pap smears, colposcopies, biopsies and surgery on the uterine cervix (Belgium, 1996-2000).

1 reference

12 December 2020

Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease

1 reference

12 December 2020

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

12 December 2020

Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia

1 reference

12 December 2020

The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany.

1 reference

12 December 2020

Estimates of cancer incidence and mortality in Europe in 1995

1 reference

12 December 2020

Epidemiology of Genital Human Papillomavirus Infection

1 reference

12 December 2020

Projected Clinical Benefits and Cost-effectiveness of a Human Papillomavirus 16/18 Vaccine

1 reference

12 December 2020

[Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]

1 reference

12 December 2020

The predicted effect of changes in cervical screening practice in the UK: results from a modelling study

1 reference

12 December 2020

Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France

1 reference

12 December 2020

Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis

1 reference

12 December 2020

Human papillomavirus and cervical cancer

1 reference

12 December 2020

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

1 reference

12 December 2020

National Institute for Clinical Excellence (NICE): Is economic appraisal working?

1 reference

12 December 2020

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

12 December 2020

Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches

1 reference

12 December 2020

Potential health and economic impact of adding a human papillomavirus vaccine to screening programs.

1 reference

12 December 2020

Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer

1 reference

12 December 2020

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

1 reference

12 December 2020

Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies.

1 reference

12 December 2020

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

1 reference

12 December 2020

Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: A cost-effectiveness analysis

1 reference

12 December 2020

Cost-effectiveness of human papillomavirus vaccination in the United States

1 reference

12 December 2020

Colposcopy for the diagnosis of squamous intraepithelial lesions: A meta-analysis

1 reference

12 December 2020

Model for assessing human papillomavirus vaccination strategies

1 reference

12 December 2020

10.2165/00019053-200927030-00006

Identifiers

DOI

1 reference

18 February 2018

Dimensions Publication ID

1008782166

0 references

1 reference

18 February 2018